1. CD21low B cells are predictive markers of new digital ulcers in systemic sclerosis
- Author
-
Antonietta Gigante, Chiara Pellicano, Edoardo Rosato, Marcella Visentini, Stefania Colantuono, Ramona Marrapodi, Milvia Casato, and Giorgia Leodori
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Multivariate analysis ,systemic sclerosis ,Immunology ,Pulmonary arterial pressure ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Skin Ulcer ,medicine ,Humans ,Immunology and Allergy ,In patient ,B cells ,CD21low ,connective tissue diseases ,digital ulcers ,major vascular complications ,raynaud's phenomenon ,B cell ,B-Lymphocytes ,Scleroderma, Systemic ,Predictive marker ,business.industry ,Area under the curve ,Middle Aged ,Peripheral blood ,Confidence interval ,030104 developmental biology ,medicine.anatomical_structure ,Autoimmunity/Autoimmune disease ,Original Article ,Female ,Receptors, Complement 3d ,ORIGINAL ARTICLES ,business ,Biomarkers ,030215 immunology - Abstract
Summary The objective of this study was to evaluate the predictive role of CD21low B cells as markers of new digital ulcers in systemic sclerosis patients. Peripheral blood B cell subpopulations and clinical assessments have been evaluated in 74 systemic sclerosis patients at baseline and after a 12‐month follow‐up. After a 12‐month follow‐up, 23 (31.1%) systemic sclerosis patients developed new digital ulcers. The median percentage of CD21low B cells was significantly higher in patients with than without new digital ulcers [10.1 (4.3–13.6) versus 4.8 (3.5–7.4); p, CD21low B cells are increased in SSc patients. CD21low B cells are higher in SSc patients with major vascular complications. CD21low B cells may be a possible predictive marker of new DUs.
- Published
- 2021
- Full Text
- View/download PDF